| Literature DB >> 29093973 |
Ioana Bancu1,2,3,4, Fredzzia Graterol1,2,3,4, Jorge Bonal1,2,3,4, Pilar Fernández-Crespo5, Jessica Garcia5, Susana Aguerrevere5, Domingo Del Castillo5, Josep Bonet1,2,3,4.
Abstract
INTRODUCTION: Labeling a patient as "frail" may be useful in assessing the prognosis and therapeutic approach.Entities:
Year: 2017 PMID: 29093973 PMCID: PMC5637862 DOI: 10.1155/2017/7624139
Source DB: PubMed Journal: J Aging Res ISSN: 2090-2204
Clinical characteristics.
| Age (years) | 70,26 ± 13,85 |
| Gender (M) | 59,4% |
| BMI (kg/m2) | 25,93 ± 5,18 |
| Hypertension | 94,4% |
| CVA | 85,9% |
| IHD | 71,6% |
| DM2 | 39,7% |
| COPD | 10,9% |
| Liver disease | 7,8% |
| Dementia | 4,1% |
| Neoplastic disease | 0,9% |
BMI: body mass index; CVA: cerebrovascular accident; IHD: ischemic heart disease; DM2: type 2 diabetes mellitus; COPD: chronic obstructive pulmonary disease; M: male.
Clinical and analytical characteristics of frail versus nonfrail patients.
| Variable | Frail ( | Nonfrail ( |
|
|---|---|---|---|
| Age | 75,39 ± 11,53 | 69,85 ± 13,94 | 0,10 |
| BMI | 22,53 ± 3,58 | 26,16 ± 5,18 | 0,004 |
| Hgb | 10,35 ± 1,31 | 10,97 ± 1,18 | 0,032 |
| Albumin | 3,61 ± 0,36 | 3,85 ± 0,29 | 0,001 |
| Npna | 1,12 ± 0,26 | 10,01 ± 0,26 | 0,093 |
| CaxP | 35,98 ± 10,58 | 38,34 ± 10,73 | 0,354 |
|
| 2,02 ± 0,23 | 1,88 ± 0,37 | 0,130 |
Npna: normalized protein nitrogen appearance; Ktv: K: urea clearance, t: dialysis time, and V: distribution volume.
Associated comorbidities of frail versus nonfrail patients.
| Variable | Frail ( | Nonfrail ( |
|
|---|---|---|---|
| PV | 38,8% | 17,21% | 0,004 |
| CVD | 16,6% | 16,55% | 0,0079 |
| Depression | 38,8% | 12,58% | 0,004 |
| APBADL | 33,33% | 76,4% | <0,005 |
| Transfers | 38,8% | 84,7% | <0,005 |
| Karnofsky | 44,4% | 95,36% | <0,005 |
PV: peripheral vasculopathy; CVD: cerebrovascular disease; APBADL: ability to perform basic activities of daily living.
Vascular access of frail versus nonfrail patients.
| Vascular access | Nonfrail | Frail |
|
|---|---|---|---|
| Catheter | 17,8% | 61,6% | <0,005 |
| Native FAVI | 77,5% | 27,78% | |
| Prosthetic FAVI | 5% | 11,11% |